1-[(4-甲基苯基)甲基]哌啶-3-醇 | 414886-29-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-[(4-甲基苯基)甲基]哌啶-3-醇
• 英文名称: 1-(4-Methylbenzyl)piperidin-3-ol
• 英文别名: 1-[(4-methylphenyl)methyl]piperidin-3-ol
• CAS: 414886-29-6
• 化学式: C₁₃H₁₉NO
• mdl: MFCD01652546
• 分子量: 205.3
• InChiKey: LTOWTJRPZHQZHR-UHFFFAOYSA-N

物化性质

• 沸点：
  315.3±37.0 °C(Predicted)
• 密度：
  1.085±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-[(4-甲基苯基)甲基]哌啶-3-醇 在 三甲基氨基磺酸 、 二甲基亚砜 、 三乙胺 作用下， 生成 1-[(4-Methylphenyl)methyl]piperidin-3-one
  参考文献：
  名称：

  Design and synthesis of Rho kinase inhibitors (II)

  摘要：

  In a previous study, we identified several structurally unrelated scaffolds of the Rho kinase inhibitor using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. 1H-Indazole is one of the candidate scaffolds on which a new series of potent Rho kinase inhibitors could be developed. In this study, the detailed structure-activity relationship of 1H-indazole analogues was studied. During this study, we found that the cell-free enzyme inhibitory potential of Rho kinase inhibitors having the 1H-indazole scaffold did not necessarily correlate with their inhibitory potential toward the chemotaxis of cultured cells. The choice of the linker substructure was shown to be an important factor for the 1H-indazole analogues to inhibit the chemotaxis of cells. Optimization of the 1H-indazole inhibitors with respect to the in vitro inhibition of monocyte chemotaxis induced by MCP-1 was carried out. The inhibitory potential was improved both in the cell-free enzyme assay and in the chemotaxis assay. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.09.052
• 作为产物：
  描述：

  3-羟基哌啶 、 4-甲基氯苄 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 1-[(4-甲基苯基)甲基]哌啶-3-醇
  参考文献：
  名称：

  Design and synthesis of Rho kinase inhibitors (II)

  摘要：

  In a previous study, we identified several structurally unrelated scaffolds of the Rho kinase inhibitor using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. 1H-Indazole is one of the candidate scaffolds on which a new series of potent Rho kinase inhibitors could be developed. In this study, the detailed structure-activity relationship of 1H-indazole analogues was studied. During this study, we found that the cell-free enzyme inhibitory potential of Rho kinase inhibitors having the 1H-indazole scaffold did not necessarily correlate with their inhibitory potential toward the chemotaxis of cultured cells. The choice of the linker substructure was shown to be an important factor for the 1H-indazole analogues to inhibit the chemotaxis of cells. Optimization of the 1H-indazole inhibitors with respect to the in vitro inhibition of monocyte chemotaxis induced by MCP-1 was carried out. The inhibitory potential was improved both in the cell-free enzyme assay and in the chemotaxis assay. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.09.052

文献信息

• [EN] NOVEL CHOLINE KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE CHOLINE KINASE
  申请人：ARIAD PHARMA INC

  公开号：WO2014151761A1

  公开（公告）日：2014-09-25

  This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds.

  这项发明涉及通式（I）的化合物，其中变量基团如本说明中所识别的，并涉及该化合物的制备和使用。
• Novel Choline Kinase Inhibitors
  申请人：ZECH Stephan G.

  公开号：US20160024024A1

  公开（公告）日：2016-01-28

  This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds.

  本发明涉及一般式（I）的化合物，其中变量基团如本文所述，并涉及所述化合物的制备和使用。
• US9834521B2
  申请人：——

  公开号：US9834521B2

  公开（公告）日：2017-12-05
• Design and synthesis of Rho kinase inhibitors (II)
  作者：Masayuki Iwakubo、Atsuya Takami、Yuji Okada、Takehisa Kawata、Yoshimichi Tagami、Hiroshi Ohashi、Motoko Sato、Terumi Sugiyama、Kayoko Fukushima、Hiroshi Iijima

  DOI：10.1016/j.bmc.2006.09.052

  日期：2007.1.1

  In a previous study, we identified several structurally unrelated scaffolds of the Rho kinase inhibitor using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. 1H-Indazole is one of the candidate scaffolds on which a new series of potent Rho kinase inhibitors could be developed. In this study, the detailed structure-activity relationship of 1H-indazole analogues was studied. During this study, we found that the cell-free enzyme inhibitory potential of Rho kinase inhibitors having the 1H-indazole scaffold did not necessarily correlate with their inhibitory potential toward the chemotaxis of cultured cells. The choice of the linker substructure was shown to be an important factor for the 1H-indazole analogues to inhibit the chemotaxis of cells. Optimization of the 1H-indazole inhibitors with respect to the in vitro inhibition of monocyte chemotaxis induced by MCP-1 was carried out. The inhibitory potential was improved both in the cell-free enzyme assay and in the chemotaxis assay. (c) 2006 Elsevier Ltd. All rights reserved.